Outlook Therapeutics® to Present at the BTIG Ophthalmology Day

Rhea-AI Summary

Outlook Therapeutics, a biopharmaceutical firm, announced that its CEO, Russ Trenary, will present at the BTIG Ophthalmology Day on November 29, 2022, at 12:30 PM ET. The company is focused on launching ONS-5010, the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications like wet AMD, DME, and BRVO. The FDA has set a goal date of August 29, 2023, for the BLA submission for ONS-5010. This formulation aims to provide a significant treatment option in the U.S., U.K., Europe, Japan, and other markets.

ISELIN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present in a fireside chat at the virtual BTIG Ophthalmology Day on November 29, 2022 at 12:30 PM ET.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29, 2023. The submission is supported by Outlook Therapeutics’ wet AMD clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, and other markets. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:
Media Inquiries:
Anna Army
Account Supervisor
LaVoie Health Science
T: 617-351-0246
aarmy@lavoiehealthscience.com

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247 
OTLK@jtcir.com

FAQ

What is the significance of the BTIG Ophthalmology Day presentation for OTLK?

The presentation by CEO Russ Trenary highlights Outlook Therapeutics’ advancements towards launching ONS-5010, a key product aimed at treating retinal diseases.

When is the PDUFA goal date for ONS-5010 by Outlook Therapeutics?

The PDUFA goal date for ONS-5010 is August 29, 2023, marking a critical deadline for potential FDA approval.

What are the indications for ONS-5010 being developed by Outlook Therapeutics?

ONS-5010 is being developed for retinal indications including wet AMD, DME, and BRVO.

What is OTLK's strategy to commercialize ONS-5010 if approved?

Outlook Therapeutics plans to commercialize ONS-5010 as the first FDA-approved ophthalmic bevacizumab for retinal diseases in major markets.

Who can participate in the one-on-one meetings at the BTIG Ophthalmology Day?

Qualified members of the investor community who register for the conference will have the opportunity to engage in virtual one-on-one meetings.